GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anatara Lifesciences Ltd (ASX:ANR) » Definitions » EV-to-EBITDA

Anatara Lifesciences (ASX:ANR) EV-to-EBITDA : -3.26 (As of May. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Anatara Lifesciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anatara Lifesciences's enterprise value is A$6.55 Mil. Anatara Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.01 Mil. Therefore, Anatara Lifesciences's EV-to-EBITDA for today is -3.26.

The historical rank and industry rank for Anatara Lifesciences's EV-to-EBITDA or its related term are showing as below:

ASX:ANR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -42.82   Med: -1.11   Max: 1.12
Current: -3.26

During the past 9 years, the highest EV-to-EBITDA of Anatara Lifesciences was 1.12. The lowest was -42.82. And the median was -1.11.

ASX:ANR's EV-to-EBITDA is ranked worse than
100% of 465 companies
in the Biotechnology industry
Industry Median: 9.34 vs ASX:ANR: -3.26

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), Anatara Lifesciences's stock price is A$0.039. Anatara Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.013. Therefore, Anatara Lifesciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Anatara Lifesciences EV-to-EBITDA Historical Data

The historical data trend for Anatara Lifesciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anatara Lifesciences EV-to-EBITDA Chart

Anatara Lifesciences Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -1.89 -0.91 -3.79 -1.13 -1.48

Anatara Lifesciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.13 - -1.48 -

Competitive Comparison of Anatara Lifesciences's EV-to-EBITDA

For the Biotechnology subindustry, Anatara Lifesciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatara Lifesciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Anatara Lifesciences's EV-to-EBITDA falls into.



Anatara Lifesciences EV-to-EBITDA Calculation

Anatara Lifesciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6.546/-2.009
=-3.26

Anatara Lifesciences's current Enterprise Value is A$6.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-2.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anatara Lifesciences  (ASX:ANR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Anatara Lifesciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.039/-0.013
=At Loss

Anatara Lifesciences's share price for today is A$0.039.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anatara Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.013.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Anatara Lifesciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Anatara Lifesciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Anatara Lifesciences (ASX:ANR) Business Description

Traded in Other Exchanges
N/A
Address
c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.

Anatara Lifesciences (ASX:ANR) Headlines

No Headlines